An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc.
First received: February 24, 2010
Last updated: January 23, 2014
Last verified: January 2014
Open-label, multi-center extension treatment protocol to allow access to tivozanib and sorafenib for subjects who have participated on the AV-951-09-301 protocol. Eligible subjects who were randomized to receive sorafenib on AV-951-09-301 and had documented progression of disease will receive a tivozanib dose of 1.5 mg/day. Eligible subjects who were randomized to tivozanib or sorafenib in AV-951-09-301, and displayed clinical benefit and acceptable tolerability to treatment, will continue to receive tivozanib or sorafenib at the same dose and schedule as in AV-951-09-301.
Advanced Renal Cell Carcinoma
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
||An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)
Primary Outcome Measures:
- To allow access to tivozanib for subjects who participated in Protocol AV-951-09-301 and AV-951-09-902, and failed sorafenib treatment on either protocol. [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- To allow long-term access to tivozanib for subjects who participated in Protocol AV 951 09 301, and demonstrated clinical benefit and acceptable tolerability to tivozanib. [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- To allow long-term access to sorafenib for subjects who participated in Protocol AV 951 09 301, and demonstrated clinical benefit and acceptable tolerability to sorafenib. [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- To assess long-term safety in subjects who continue treatment with tivozanib. [ Time Frame: 24 Months ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- To determine the ORR, duration of response (DR), and PFS of subjects who continue treatment with tivozanib or sorafenib. [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- To determine the ORR, DR, and PFS of subjects who receive tivozanib after failure of sorafenib. [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- To determine overall survival (OS) of subjects who continue treatment with tivozanib or sorafenib. [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||June 2014 (Final data collection date for primary outcome measure)
Tivozanib will be orally administered once daily, at least 1 hour before or 2 hours after ingesting any food or other medication, for as long as the subject tolerates treatment in the absence of disease progression or unacceptable toxicity. Study drug will be administered beginning on Day 1 of Cycle 1.
Active Comparator: Sorafenib
Sorafenib will be orally administered twice daily (unless reduced in parent protocol). Sorafenib should be taken without food at least 1 hour before or 2 hours after ingesting any food or other medications. Study drug will be administered beginning on Day 1 of Cycle 1.
This is an extension treatment protocol to allow access to tivozanib or sorafenib for subjects enrolled on AV-951-09-301(parent protocol). Subjects who failed sorafenib on the parent protocol will be offered tivozanib. Subjects who were randomized to tivozanib, and demonstrated clinical benefit and acceptable tolerability will be offered long-term access to tivozanib. Subjects who were randomized to sorafenib, and demonstrated clinical benefit and acceptable tolerability will be offered long-term access to sorafenib. Subjects who continue receiving sorafenib on this protocol and progress will be allowed to cross-over to tivozanib.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
The subject must have participated on Protocol AV-951-09-301, and must meet either of the following bulleted criteria:
Demonstrated disease progression per RECIST during treatment with sorafenib, OR
Demonstrated clinical benefit [complete response (CR), partial response (PR), or stable disease (SD) per RECIST] and acceptable tolerability after treatment with tivozanib or sorafenib on protocol AV-951-09-301
- ECOG performance status ≤ 2 (see Appendix C) and life expectancy ≥ 3 months.
- If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.
- Ability to give written informed consent
- Newly identified CNS malignancies or documented progression of CNS metastases; subjects will be allowed only if the CNS metastases have been adequately treated with radiotherapy or surgery. For subjects receiving steroid therapy please refer to Section 6.3 for allowed steroid maintenance therapy
Duration since last dose on Protocol AV-951-09-301:
- For subjects continuing tivozanib or sorafenib (subjects who demonstrated clinical benefit and acceptable tolerability during treatment with tivozanib or sorafenib on protocol AV-951-09-301): more than 2 weeks since last dose of tivozanib or sorafenib
- For subjects initiating tivozanib (ie demonstrated disease progression during treatment with sorafenib): more than 4 weeks since last dose of sorafenib. Subjects demonstrating disease progression due to CNS metastasis will be allowed up to 8 weeks since last dose of sorafenib in order to complete treatment for CNS metastasis
- Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug
Any of the following hematologic abnormalities:
- Hemoglobin < 9.0 g/dL
- ANC < 1500 per mm3
- Platelet count < 75,000 per mm3
- PT or PTT >1.5 × ULN
Any of the following serum chemistry abnormalities:
- Total bilirubin > 1.5 × ULN (or > 2.5 × ULN for subjects with Gilbert's syndrome)
- AST or ALT > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis)
- Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone metastasis)
- Creatinine > 2.0 × ULN
- Proteinuria > 3+ by urinalysis or urine dipstick
- If female, pregnant or lactating
- Sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures, while on study and for at least 50 days after the last dose of study drug. Sexually active male subjects must use adequate contraceptive measures, while on study and for at least 90 days after the last dose of study drug. All fertile male and female subjects,and their partners,must agree to use a highly effective method of contraception. Effective birth control includes (a) IUD plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.)
- Uncontrolled hypertension: systolic blood pressure > 150 mmHg or diastolic blood pressure >100 mmHg on 2 or more antihypertensive medications, documented on 2 consecutive measurements taken at least 24 hours apart.
- Unhealed wounds (including active peptic ulcers)
- Serious/active infection or infection requiring parenteral antibiotics
- Life-threatening illness or organ system dysfunction compromising safety evaluation
- Psychiatric disorder, altered mental status precluding informed consent or necessary testing
- Inability to comply with protocol requirements
- Treatment with another anti-cancer therapy or participation in another interventional protocol (excluding AV-951-09-301)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01076010
AVEO Pharmaceuticals, Inc.
||Robert J. Motzer, MD
||Memorial Sloan-Kettering Cancer Center
No publications provided
||AVEO Pharmaceuticals, Inc.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 24, 2010
||January 23, 2014
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 06, 2014
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action